The Cushing’s Hub Editorial Board is delighted to host its first webinar on Friday 16 December 2022 at 13.00-14.00 hours Central European Time.
Chaired by Dr Niki Karavitaki, University of Birmingham, UK, panellists Prof Stephan Petersenn, Hamburg, Germany, Prof Antoine Tabarin, Bordeaux, France and Assoc Prof Greisa Vila, Vienna, Austria, discuss challenges surrounding the clinical management of Cushing’s syndrome and take questions from the audience.
The Cushing’s Hub Clinical Case Competition winning entry is now available online. Read what Dr Marta Araujo-Castro, Specialist in Endocrinology at the Ramón y Cajal University Hospital, Madrid, says about the diagnosis of primary bilateral macronodular adrenal hyperplasia in this new Cushing’s Hub e-Learning module.
This editorial looks at the challenges associated with rare disease recognition with regard to all health care professionals who encounter Cushing’s patients.
Two phase 2 studies published in The Journal of Clinical Endocrinology & Metabolism in October 2022 suggest that seliciclib, a selective cyclin-dependent kinase inhibitor targeting pituitary adrenocorticotropic 2 hormone production, may improve hypercortisolemia in patients with Cushing’s disease.
The use of radiotherapy in the treatment of pituitary adenoma or craniopharyngioma is associated with risk of second brain tumour, although its quantitative assessment has traditionally been hampered by methodological limitations. This Publication Highlight describes the work of Hamblin R, et al. whose retrospective cohort study helps clarify the risks associated with irradiation.